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ABSTRACT
Introduction: To evaluate the risk of breast
cancer associated with long-term use of
antihypertensive agents (AHs) in Taiwanese
women with hypertension.
Methods: A search of the Taiwan National
Health Insurance Research Database identified
330,699 patients with hypertension who were
treated with antihypertensive drugs between
January 1, 1998 and December 31, 2011.
Logistic regression models were used to
estimate the odds ratios (ORs) and 95%
confidence intervals (CIs) between the use of
AHs and breast cancer risk, adjusted for other
types of antihypertensive drugs, statins and co-
morbidities.
Results: Among the AHs used to treat the
hypertensive women enrolled in our study,
our analysis revealed that those treated with
one specific particular class of beta-blockers
(beta-1 selective beta-blockers) had an
increased risk for breast cancer. We also found
that the ever-use of calcium channel blockers
(CCBs; i.e. for 13 years) was associated with
breast cancer in an adjusted model (OR 1.09;
95% CI 1.03–1.16). However, the use of
nonselective beta-blockers, selective and
nonselective alpha-blockers, angiotensin-
converting enzyme inhibitors and angiotensin
II antagonists were not associated with breast
cancer risk.
Conclusion: Based on the results of our
analysis, long-term use of CCBs or beta-1
selective beta-blockers are likely to be
associated with the risk of breast cancer.
Further large comprehensive population-based
studies to support our findings are required for
confirmation of this conclusion.
Keywords: Beta blockers; Nonselective beta-1
blocker; Long-term; Hypertension
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INTRODUCTION
Cardiac disease and hypertension have been the
third and eighth leading causes of death in
Taiwan since 2000 [1]. According to a recent
study, the percentage of the population with a
prescription for antihypertensive drugs in
Taiwan has increased from 2001 to 2006 [2].
The authors of this study report that during this
period, the average annual increase in
prescriptions for calcium channel blockers
(CCBs), angiotensin II receptor blockers (ARBs)
and angiotensin-converting-enzyme inhibitors
(ACEIs) were 10.7, 22.1 and 4.5 %, respectively
[2]. In 2013, the sale volume of the three
leading antihypertensive drugs in Taiwan
amounted to about US$ 5 million; in
comparison, in the USA the value of
prescriptions filled for antihypertensive drugs
in 2013 totaled about US$ 678.2 million [3].
The use of antihypertensive agents (AHs) has
grown globally over the last decade. However,
available data on a potential association
between the use of AHs and risk of breast
cancer are conflicting. Recent epidemiological
studies suggest that beta-blockers prevent breast
cancer progression or reduce recurrence and
then improve survival [4–6]. In contrast, other
studies have reported an increased risk or no
association at all between the use of beta-
blockers/CCBs and breast cancer risk [7–9]. In
addition, evidence for any association between
the use of ACEIs/ARBs and breast cancer is also
inconsistent, with some studies suggesting that
ACEIs/ARBs are not associated with cancer risk
[10, 11], and others reporting an increased or
reduced risk [12].
To address the conflicting evidence from
previous studies, the aim of the study reported
here was to evaluate the risk of breast cancer




Data were retrieved from the National Health
Insurance Research Database (NHIRD) and
Registry for Catastrophic Illness Patient dataset
(HV dataset) between January 1, 1998 and
December 31, 2011 in Taiwan. The NHIRD
contains comprehensive information on
demographic characteristics, pharmacy records
and medical services from inpatient, outpatient
and emergency care under a national health
insurance program in which over 99% of the 23
million inhabitants of Taiwan are enrolled. The
HV dataset comprises specific data subsets of the
NHIRD for research purposes and contains
registration files and original claim data on
patients registered in the NHIRD who have/had
a catastrophic illness. All patients records/
information were de-identified and analyzed
anonymously. Therefore, this study was exempt
from the approval by the Ethics Review Board at
our institution.
Study Group
From the HV dataset, we identified 330,699
women with newly diagnosed hypertension
[International Classification of Disease, Ninth
Revision (ICD-9 CM) codes 401–405] who had
been treated with any AHs continuously for at
least 6 months between January 1, 1998 and
December 31, 2011. Among these, we further
identified women with a first diagnosis of breast
cancer (ICD-9 CM codes 174.xx and 175.xx);
these women were the cases in our study
(Fig. 1). The date of diagnosis was the index
date.
We excluded patients who had a history of
breast cancer or any cancer recorded in the HV
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dataset any time before the initiation of
antihypertensive treatment and patients
without continuous enrolment in a NHI
program. Patients were followed from the date
of diagnosis of hypertension in 1998 up to
December 31, 2011 (median duration 13 years)
or death, whichever came first (Fig. 1).
We randomly selected hypertensive women
registered in the NHIRD without any diagnosis
of breast cancer who were receiving treatment
for hypertension in the same period as the
cases. These were matched (1:4) for age (5-year
categories), index date and year of hypertension
diagnosis with the cases to establish the control
group (Fig. 1).
Exposure Variables
The main exposure of interest was that to beta-
blocker, CCB, ACEI and ARB therapy. We
collected information on prescribed drug types
according to Anatomical Therapeutic Chemical
Classification System codes (C07 for beta-
blockers; C02D, C08C, C08D, C08DA51 for
CCBs; C02E, C02L, C09A, C09BA for ACEIs;
C09CA for ARBs), dosage, date of prescription,
supply days and total number of prescriptions
from the outpatient and inpatient records [13].
The cumulative defined daily dose (cDDD) of
each AH was calculated as recommended by the
World Health Association [14]. Beta-blockers
were further classified as nonselective and beta-
1 selective beta-blockers, and as selective and
nonselective alpha-blockers.
Potential Covariates
Several potential covariates, including age
and comorbidities at cancer diagnosis, were
also measured in the year preceding the
index date. Other covariates tested included
the use of statins and hormone replacement
therapy.
Sensitivity Analysis
We evaluated the sensitivity effects by changing
the inclusion criteria of drug prescription for
three types of AH beginning at least from
6–9 months before the index date.
Fig. 1 Study ﬂow diagram. AHT Antihypertensive, H/T hypertension, HV Registry for Catastrophic Illness Patient
dataset, NHIRD National Health Insurance Research Database
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Statistical Analysis
Logistic regression was used to estimate the
crude and adjusted odds ratio (OR) and 95%
confidence interval (CI) for breast cancer risk.
We calculated a running sum of the duration
and DDD of each drug from the date of the
initial AH prescription to the index date. We
categorized the cumulative use for each patient
as follows: B1, 1–2, 2–3 and C3 years of
duration. Cumulative DDD of each AH was
classified by quartile. Multivariable logistical
regression was used to adjust the covariates.
We also estimated the trend of the duration and
cDDD of each drug use. Data were analyzed
using the SAS Statistical Package, version 9.3
(SAS Institute, Cary, NC). The significance level
was set at P\0.05 (two-tailed test).
RESULTS
We identified 6,463 hypertensive women with
breast cancer as cases and 18,987 hypertensive
women without breast cancer as controls.
Among the 6,463 cases, the most commonly
prescribed AHs was CCBs (52.8%), followed by
ACEIs (45.5%) and beta-blockers (41.1%)
(Table 1). No significant differences in age and
mean Charlson comorbidity score (P[0.05)
were found between cases and controls. Ever-
use of CCBs and beta-blockers for longer than
10 years was significantly associated with breast
cancer (OR 1.09; 95% CI 1.03–1.16) in an
adjusted model. The risk of breast cancer was
even higher in patients receiving hormone
replacement therapy (OR 1.28, 95% CI
1.18–1.39) and statins (OR 1.68, 95 % CI
1.50–1.83) (Table 1).
When we stratified the risk of breast cancer
associated with different sub-types of beta-
blockers, we found a statistically significant
risk of breast cancer with most beta-1 selective
beta-blockers, such as atenolol (OR 1.14; 95% CI
1.05–1.25) acebutolol (OR 1.29; 1.00–1.66) and
bisoprolol (OR 1.08; 1.01–1.16) (Fig. 2). The
non-selective beta-blockers, alpha-selective and
beta-non selective showed no significant
association with breast cancer (Fig. 2).
We then stratified beta-blocker, ARB and
CCB users by exposure duration and the
cumulative DDD. The results show that the
risk of breast cancer was significantly increased
in beta-blocker and CCB users with increasing
exposure duration and increasing cDDD
compared to the controls [trend test for beta-
blocker users: P = 0.003 (exposure duration),
P = 0.0003 (cDDD); trend test for CCB users:
P = 0.006 (exposure duration), P = 0.002
(cDDD)] (Table 2).
The risk of breast cancer increased with ever-
use of atenolol or acebutolol (Table 3). This risk
increased with increasing exposure,duration of
use (trend test: P = 0.0003 for atenolol; P = 0.01
for acebutolol) and cDDD (trend test: P = 0.002
for atenolol; P = 0.02 for acebutolol).
In the sensitivity analysis for exposure
duration of AHs, the results were unchanged
when the inclusion criteria of AH prescription
was changed from\6 to[9 months (Table 4).
DISCUSSION
The results of this study suggest that the use of
ACEi, ARBs, and nonselective beta-adrenergic
receptor antagonists (propranolol or carteolol)
is not associated with breast cancer. These
results are consistent with those of most
observational studies [10, 11].
We also found that CCBs and the beta-1
selective beta-blockers acebutolol, atenolol and
bisoprolol may increase the risk of breast
cancer. This finding seems to differ from those
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Table 1 Characteristics of hypertensive patients with breast cancer and non-breast cancer during the study period
(1998–2011)
Characteristic Case (N5 6,463) Control (N5 18,987) Odds ratio (95 % CI)
n % n % Crude Adjusted
Mean age, years (SD) 61.9 (10.7) 61.9 (10.9)
18–44 272 4.21 785 4.13
45–54 1,489 23.0 4,409 23.2
55–64 2,320 35.9 6,729 35.4
65–74 1,610 24.9 4,778 25.2
75–84 645 9.98 1,912 10.1
85? 127 1.97 374 1.97
Menopause 4,702 72.7 13,793 72.6
Mean CCI score (SD) 0.33 (0.87) 0.34 (0.92) 0.98 (0.95–1.01) –
Diabetes 1,761 27.3 4,803 25.3 1.11 (1.04–1.18)** 1.08 (1.02–1.16)*
Hyperlipidemia 3,196 49.5 9,207 48.5 1.04 (0.98–1.10) –
Ever users of HRT
No 5,450 84.3 16,626 87.6 1.00 (Reference) 1.00 (Reference)
Yes 1,013 15.7 2,361 12.4 1.31 (1.21–1.42)*** 1.28 (1.18–1.39)***
Ever users of statins
No 5,725 88.6 17,700 93.2 1.00 (Reference) 1.00 (Reference)
Yes 738 11.4 1,287 6.78 1.77 (1.61–1.95)*** 1.68 (1.52–1.85)***
Types of AHT
ACEI
No 3,520 54.5 10,152 53.5 1.00 (Reference)
Yes 2,943 45.5 8,835 46.5 0.96 (0.91–1.02) –
ARB
No 4,682 72.4 14,290 75.3 1.00 (Reference) 1.00 (Reference)
Yes 1,781 27.6 4,697 24.7 1.16 (1.09–1.23)*** 1.04 (0.98–1.12)
CCBs
No 3,052 47.2 9,697 51.1 1.00 (Reference) 1.00 (Reference)
Yes 3,411 52.8 9,290 48.9 1.17 (1.10–1.23)*** 1.09 (1.03–1.16)**
Beta-blocker
No 3,806 58.9 11,721 61.7 1.00 (Reference) 1.00 (Reference)
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of previous studies which reported that beta-1
selective beta-blockers and CCBs had marked
protective effects [15, 16]. However, the authors
of a recently published study reported observing
a weak inverse association between cardio
nonselective beta-blockers and breast cancer
risk [9]. However, since the association did not
reach statistical significance, the results did not
support the hypothesis of beta-blocker usage
protecting against breast cancer progression [9].
The results of a recently published network
analysis indicated a lack of consistency in the
effect of CCBs on breast cancer; this was
attributed to the short duration of the follow-
up in the trials included in the network meta-
analysis [7].
The results of previous preclinical studies are
inconclusive in terms of whether beta-blockers
have agonist activity in breast cancer growth.
Some studies has demonstrated that beta-2
adrenergic signaling plays a role in several
pathways involved in breast tumor progression
and metastasis [17, 18], but others have found
that beta-adrenergic receptor (AR) stimulation
may both inhibit and promote breast tumor
growth [19–23]. A recently published study adds
Fig. 2 Forest plot of breast cancer risk associated with use of beta-blockers, 1998–2011. OR Odds ratio, CI conﬁdence
interval
Table 1 continued
Characteristic Case (N5 6,463) Control (N5 18,987) Odds ratio (95 % CI)
n % n % Crude Adjusted
Yes 2,657 41.1 7,266 38.3 1.13 (1.06–1.19)*** 1.05 (0.99–1.12)
* P\0.05, ** P\0.01, *** P\0.001
SD Standard deviation, CCI Charlson comorbidity index, HRT hormone replacement therapy,AHT Antihypertensive
therapy, ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor II blocker, CCB calcium channel
blocker, CI conﬁdence interval
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Table 2 Odds risk and 95% conﬁdence intervals for risk of breast cancer associated with exposure to different types of













Never use 15,527 3,806 1.00 (Reference)
Ever-use exposure duration (years) 0.003
B1 2,085 521 0.99 (0.89–1.11)
1–2 2,300 548 0.91 (0.82–1.01)
2–3 1,512 402 1.03 (0.92–1.17)
[3 4,026 1,186 1.16 (1.07–1.26)***
Cumulative DDDb 0.0003
cDDD\Q1 2,480 597 0.93 (0.84–1.02)
Q1 B cDDD\Q2 2,482 621 0.97 (0.88–1.07)
Q2 B cDDD\Q3 2,480 684 1.08 (0.98–1.19)
cDDD C Q4 2,481 755 1.22 (1.11–1.34)***
Any ARBc
Never use 18,972 4,682 1.00 (Reference)
Ever-use exposure duration (years) 0.71
B1 1,355 370 1.05 (0.93–1.19)
1–2 1,652 439 1.00 (0.89–1.12)
2–3 1,083 288 0.98 (0.85–1.12)
[3 2,388 684 1.03 (0.93–1.14)
Cumulative DDDb 0.53
cDDD\Q1 1,618 444 1.06 (0.94–1.19)
Q1 B cDDD\Q2 1,621 414 0.95 (0.84–1.07)
Q2 B cDDD\Q3 1,618 441 1.00 (0.89–1.13)
cDDD C Q4 1,621 482 1.07 (0.95–1.21)
Any CCBd
Never use 12,749 3,052 1.00 (Reference)
Ever-use exposure duration (years) 0.006
B1 2,257 572 1.05 (0.94–1.16)
1–2 2,662 696 1.08 (0.98–1.19)
2–3 1,958 522 1.09 (0.98–1.22)
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further to the body of evidence on the effect of
agonist type, indicating that the beta 2-AR
antagonist in particular seems to be the most
cytotoxic beta-blocker in non-stimulated cancer
cells [24]. However, the majority of clinical
observational studies carried out to date have
focused on comparing the association between
the use of propranolol or atenolol and breast
cancer risk or mortality and have not explored
the relationship between the subtype of beta-AR
expression and breast cancer risk [25, 26]. Our
study is the first from Asia to report that
treatment with the beta-1 selective blocker—
but not the nonselective b1/b blocker—may
increase the risk of breast cancer (Fig. 2). These
results appear to be consistent with those of
preclinical studies suggesting that the effects of
beta-adrenergic signaling on tumor progression
and metastasis are inhibited by the b2-receptor
antagonists but not by b1 antagonists [18–24].
Consequently, better designed observational
studies or randomized controlled trials are
required before this type of beta-blocker can
be considered as a therapeutic option for
patients with breast cancer.
We also observed that CCBs are likely to be
associated with breast cancer risk. This finding is
consistent with those from a recently published
study performed by Li et al. [3]. Both studies
seem to revive an earlier previous hypothesis and
focus on the long-term use of CCBs among
current or ever-users (10 years if the study of Li
et al. [3]; 13 years in our study). However, other
previously published studies found no increased
risk of breast cancer associated with CCB use [25,
26]. Therefore, to date, the results on the effect of
CCBs on breast cancer risk are inconsistent.
Again, larger and more comprehensive studies
are needed to confirm the effects of long-term
use of CCBs on breast cancer.
A major advantage of our study was that we













[3 5,852 1,621 1.11 (1.03–1.19)**
Cumulative DDDb 0.002
cDDD\Q1 3,175 818 1.05 (0.96–1.15)
Q1 B cDDD\Q2 3,176 834 1.07 (0.98–1.18)
Q2 B cDDD\Q3 3,174 838 1.06 (0.97–1.17)
cDDD C Q4 1,621 482 1.16 (1.06–1.28)**
** P\0.01, *** P\0.001
cDDD Cumulative deﬁned daily dose
a Adjusted for peripheral vascular disease, diabetes mellitus and medicine use (included HRT, statin, ARB and CCB)
b Beta-blocker: Q1 (25%) = 195.25 DDD, Q2 (50%) = 448 DDD, Q3 (75%) = 1,012 DDD. CCB: Q1 (25%) = 390.1
DDD, Q2 (50%) = 851 DDD, Q3 (75%) = 1,641.3 DDD. ARB: Q1 (25%) = 405 DDD, Q2 (50%) = 800.5 DDD, Q3
(75%) = 1,464 DDD
c Adjusted for peripheral vascular disease, diabetes mellitus and medicine use (including HRT, statin, beta-blocker and
CCB)
d Adjusted for peripheral vascular disease, diabetes mellitus and medicine use (including HRT, statin, beta-blocker and
ARB)
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healthcare beneficiaries registered in a large
population-based database for whom complete
data on drug prescriptions and cancer diagnoses
were available. Thus, the possibility of selection
and information biases was minimized.
However, there were still some limitations to
our study. First, the health insurance database
that we used was developed for administrative
purposes and contained de-identified records of
each individual registered. Second, the database
only provided information on the frequency
and classes of prescribed medications and did
not provide any clinical laboratory data or
clinical information; therefore, we could not
estimate patient’s responses to drug therapy.
Finally, the database did not contain
information on various lifestyle risk factors for
cancer, such as physical activity, alcohol
consumption, smoking, body mass index,
socioeconomic status and diet; therefore, these
were not included in the analysis. Although we
adjusted the potential covariates, such as co-
Table 3 Breast cancer risk associated with exposure duration and dosage of speciﬁc beta-blockers during the study period
(1998–2011)


















B1 30/104 1.10 (0.71–1.68) 248/942 1.01 (0.87–1.17) 1,318/4,913 1.06 (0.99–1.14)
2–3 21/71 1.10 (0.66–1.84) 222/795 1.07 (0.91–1.26) 121/402 1.14 (0.92–1.42)






P for trend 0.01 0.0003 0.03
Dosage (cDDD)a
\Q1 21/71 1.10 (0.66–1.84) 187/891 1.04 (0.87–1.23) 384/1457 1.04 (0.92–1.18)
CQ1–\Q2 19/72 0.97 (0.57–1.64) 187/689 1.03 (0.87–1.23) 408/1429 1.14
(1.01–1.29)*
CQ2–\Q3 26/72 1.56 (0.96–2.53) 202/695 1.13 (0.96–1.34) 382/1435 1.02 (0.90–1.15)
CQ3 26/72 1.59 (0.98–2.58) 226/692 1.30 (1.10–1.53)** 402/1432 1.10 (0.98–1.25)
P for trend 0.02 0.002 0.053
* P\0.05, ** P\0.01, *** P\0.001
Adjusted for diabetes mellitus and medicine use (including HRT, statins, ARBs and CCBs)
n Number of breast cancer patients using a speciﬁc AHT, N total number of study population using a speciﬁc AHT
a Beta-blocker: Q1 (25%) = 195.25 DDD, Q2 (50%) = 448 DDD, Q3 (75%) = 1,012 DDD. CCB: Q1 (25%) = 390.1
DDD, Q2 (50%) = 851 DDD, Q3 (75%) = 1,641.3 DDD. ARB: Q1 (25%) = 405 DDD, Q2 (50%) = 800.5 DDD, Q3
(75%) = 1,464 DDD
Cardiol Ther (2015) 4:65–76 73
morbidities and the use of other medications,
the misclassification of these covariates may
have some impact on our results.
CONCLUSION
Our findings indicate that the long-term use
of CCBs or beta-1 selective blockers are likely
to be associated with breast cancer risk.
Further comprehensive and large population-
based studies are needed to confirm these
findings before any definitive conclusion can
be drawn.
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Table 4 Sensitivity analysis for criteria of antihypertensive use







Non-user 4,107/16,690 1.00 (Reference) 4,876/19,700 1.00 (Reference) 3,367/14,012 1.00 (Reference)
User 2,356/8,760 1.04 (0.98–1.11) 1,587/5,750 1.01 (0.94–1.09) 3,096/11,438 1.09 (1.03–1.16)**
Drug use (years)
B2 220/922 0.94 (0.80–1.10) 176/627 1.08 (0.90–1.29) 257/994 1.07 (0.92–1.24)
2–3 548/2,300 0.91 (0.82–1.01) 439/1,652 1.00 (0.89–1.12) 696/2,662 1.07 (0.98–1.18)
3–4 402/1,512 1.03 (0.91–1.16) 288/1,083 0.97 (0.84–1.12) 522/1,958 1.09 (0.98–1.22)
[4 1,186/4,026 1.15 (1.06–1.25)*** 684/2,388 1.03 (0.93–1.14) 1,621/5,824 1.11 (1.03–1.19)**
P for trend 0.005 0.76 0.005
* P\0.05, ** P\0.01, *** P\0.001
N Total number of study population using speciﬁc AHT, n number of breast cancer patients using speciﬁc AHT
a Adjusted for peripheral vascular disease, diabetes mellitus and medicine use (including HRT, statins, ARBs and CCBs)
b Adjusted for peripheral vascular disease, diabetes mellitus and medicine use (including HRT, statins, beta-blockers and
CCBs)
c Adjusted for peripheral vascular disease, diabetes mellitus and medicine use (including HRT, statins, beta-blockers and
ARBs)
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and reproduction in any medium, provided the
original author(s) and the source are credited.
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